Goodwill and Intangible Assets	6 Months Ended
Jun. 30, 2026
Intangible Asset, Goodwill and Other [Abstract]
Goodwill and Intangible Assets	Note 7 — Goodwill and Intangible Assets The total amount of goodwill reported was $35.2 billion at June 30, 2026, and $24.0 billion at December 31, 2025. Goodwill increased by $11.4 billion in the first six months of 2026 due to the completion of the Exact Sciences acquisition. Foreign currency translation adjustments decreased goodwill by $0.2 billion in the first six months of 2026. The amount of goodwill related to reportable segments at June 30, 2026, was $2.7 billion for the Established Pharmaceutical Products segment, $0.3 billion for the Nutritional Products segment, $15.0 billion for the Diagnostic Products segment, and $17.3 billion for the Medical Devices segment. The Diagnostic Products segment includes the amount of goodwill related to the Exact Sciences acquisition. There were no reductions of goodwill relating to impairments in the first six months of 2026. The gross amount of amortizable intangible assets, primarily product rights and technology, was $39.8 billion as of June 30, 2026, and $27.6 billion as of December 31, 2025. The gross amount of amortizable intangible assets increased by $12.3 billion in the first six months of 2026 due to the completion of the Exact Sciences acquisition. Accumulated amortization was $24.3 billion and $23.3 billion as of June 30, 2026, and December 31, 2025, respectively. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.6 billion in 2026, $2.3 billion in 2027, $1.8 billion in 2028, $1.7 billion in 2029, and $1.5 billion in 2030. Indefinite-lived intangible assets, which relate to in-process research and development (IPR&D), were $1.7 billion and $1.2 billion as of June 30, 2026, and December 31, 2025, respectively. The increase in IPR&D was due to the Exact Sciences acquisition.

Goodwill and Intangible Assets

6 Months Ended

Jun. 30, 2026

Intangible Asset, Goodwill and Other [Abstract]

Note 7 — Goodwill and Intangible Assets

The total amount of goodwill reported was $35.2 billion at June 30, 2026, and $24.0 billion at December 31, 2025. Goodwill increased by $11.4 billion in the first six months of 2026 due to the completion of the Exact Sciences acquisition. Foreign currency translation adjustments decreased goodwill by $0.2 billion in the first six months of 2026. The amount of goodwill related to reportable segments at June 30, 2026, was $2.7 billion for the Established Pharmaceutical Products segment, $0.3 billion for the Nutritional Products segment, $15.0 billion for the Diagnostic Products segment, and $17.3 billion for the Medical Devices segment. The Diagnostic Products segment includes the amount of goodwill related to the Exact Sciences acquisition. There were no reductions of goodwill relating to impairments in the first six months of 2026.

The gross amount of amortizable intangible assets, primarily product rights and technology, was $39.8 billion as of June 30, 2026, and $27.6 billion as of December 31, 2025. The gross amount of amortizable intangible assets increased by $12.3 billion in the first six months of 2026 due to the completion of the Exact Sciences acquisition. Accumulated amortization was $24.3 billion and $23.3 billion as of June 30, 2026, and December 31, 2025, respectively. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.6 billion in 2026, $2.3 billion in 2027, $1.8 billion in 2028, $1.7 billion in 2029, and $1.5 billion in 2030.

Indefinite-lived intangible assets, which relate to in-process research and development (IPR&D), were $1.7 billion and $1.2 billion as of June 30, 2026, and December 31, 2025, respectively. The increase in IPR&D was due to the Exact Sciences acquisition.